bi(otf)3 and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

bi(otf)3 has been researched along with Leukemia--Myelogenous--Chronic--BCR-ABL-Positive* in 1 studies

Other Studies

1 other study(ies) available for bi(otf)3 and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

Article	Year
Modular synthesis of new C-aryl-nucleosides and their anti-CML activity. Bioorganic & medicinal chemistry letters, 2018, 06-01, Volume: 28, Issue:10 The C-aryl-ribosyles are of utmost interest for the development of antiviral and anticancer agents. Even if several synthetic pathways have been disclosed for the preparation of these nucleosides, a direct, few steps and modular approaches are still lacking. In line with our previous efforts, we report herein a one step - eco-friendly β-ribosylation of aryles and heteroaryles through a direct Friedel-Craft ribosylation mediated by bismuth triflate, Bi(OTf) Topics: Antineoplastic Agents; Catalysis; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mesylates; Microtubule-Associated Proteins; Nucleosides	2018

Article

Year

Modular synthesis of new C-aryl-nucleosides and their anti-CML activity.

Bioorganic & medicinal chemistry letters, 2018, 06-01, Volume: 28, Issue:10

The C-aryl-ribosyles are of utmost interest for the development of antiviral and anticancer agents. Even if several synthetic pathways have been disclosed for the preparation of these nucleosides, a direct, few steps and modular approaches are still lacking. In line with our previous efforts, we report herein a one step - eco-friendly β-ribosylation of aryles and heteroaryles through a direct Friedel-Craft ribosylation mediated by bismuth triflate, Bi(OTf)

Topics: Antineoplastic Agents; Catalysis; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mesylates; Microtubule-Associated Proteins; Nucleosides

2018